
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI is well-positioned for long-term growth and success in the technology and healthcare industries with its innovative technology, recent acquisitions, strong market presence, and potential revenue growth from its personalized cancer vaccine program. Their use of AI and real-world data sets them apart from competitors, and their anticipated revenue growth shows potential for financial success. However, their success is heavily reliant on favorable reimbursement rates and maintaining market share.
Bears say
Tempus AI is facing multiple headwinds in the coming years, including delays in regulatory approval for their platform, intense competition in the healthcare and AI sectors, and a high valuation for their stock. Additionally, their partnership with Personalis may not yield expected results as it remains uncertain how their platform will integrate with Personalis' technology. The company also has a high cash burn rate, and it is unclear if they will be able to reach profitability in the near future. All these factors contribute to our negative outlook on the stock, as we believe it is overvalued and facing significant risks in the foreseeable future.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares